Статья
Адипокины/цитокины и нарушения липидного обмена
В обзоре представлены результаты исследований в области изучения ассоциации адипокинов, секретируемых висцеральными адипоцитами, и уровня холестерина липопротеинов низкой плотности. В отношении указанной ассоциации проанализированы такие адипокины, как адипонектин, ингибитор активатора плазминогена-1 (PAI-1), резистин, интерлейкин-1 бета (ИЛ-1β), моноцитарно-хемоаттрактантный протеин 1 типа (MCP-1), фактор роста нервов (NGF), висфатин, оментин-1, а также гормон поджелудочной железы инсулин. Представлены результаты исследований, в которых изучены вопросы патогенетической (на животных моделях) и клинической роли данной ассоциации у человека. Использованы сведения по теме из публикаций баз данных PubMed, Google Scholar.
1. Cnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., Retzlaff B.M., Knopp R.H., Brunzell J.D., Kahn S.E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003; 46 (4): 459–469. doi: 10.1007/s00125-003-1074-z
2. Ebrahimi R., Shanaki M., Mohassel Azadi S., Bahiraee A., Radmard A.R., Poustchi H., Emamgholipour S. Low level of adiponectin predicts the development of Nonalcoholic fatty liver disease: is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices? Arch. Physiol. Biochem., 2022; 128 (1): 24–31. doi: 10.1080/13813455.2019.1661496
3. Kozakova M., Muscelli E., Flyvbjerg A., Frystyk J., Morizzo C., Palombo C., Ferrannini E. Adiponectin and left ventricular structure and function in healthy adults. J. Clin. Endocrinol. Metab., 2008; 93: 2811–2818. doi: 10.1210/jc.2007-2580
4. Yanai H., Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: Mechanisms and perspectives. Int. J. Mol. Sci., 2019; 20 (5): 1190. doi: 10.3390/ijms20051190
5. Каратаева О.В. Особенности секреции адипонектина и его связь с некоторыми показателями метаболизма у мужчин трудоспособного возраста при наличии ожирения. Российский меди- цинский журнал, 2017; 23 (6): 312–315. doi: 10.18821/0869-2106-2017-23-6-312-315
6. Magge S.N., Stettler N., Koren D., Levitt Katz L.E., Gallagher P.R., Mohler E.R., Rader D.J. Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents. J. Clin. Endocrinol. Metab., 2011; 96 (5): 1549–1554. doi: 10.1210/jc.2010-2364
7. Lautamäki R., Rönnemaa T., Huupponen R., Lehtimäki T., Iozzo P., Airaksinen K.E., Knuuti J., Nuutila P. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism, 2007; 56 (7): 881–886. doi: 10.1016/j.metabol.2007.01.018
8. Liu Y.U., Cheng J., Guo X., Mo J., Gao B., Zhou H., Li Z. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and metaanalysis involving 149,908 subjects. Gene, 2018; 673: 167–173. doi: 10.1016/j.gene.2018.06.040
9. Jung R.G., Motazedian P., Ramirez F.D., Simard T., di Santo P., Visintini S., Faraz M.A., Labinaz A., Jung Y., Hibbert B. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb. J., 2018; 16: 12. doi: 10.1186/s12959-018-0166-4
10. Sillen M., Declerck P.J. Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition. Front. Cardiovasc. Med., 2020; 7: 364. doi: 10.3389/fcvm.2020.622473
11. Raiko J.R., Oikonen M., Wendelin-Saarenhovi M., Siitonen N., Kahonen M., Lehtimaki T., Viikari J., Jula A., Loo B.M., Huupponen R., Saarikoski L., Juonala M., Raitakari O.T. Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis, 2012; 224 (1): 208–212. doi: 10.1016/j.atherosclerosis.2012.06.062
12. Somodi S., Seres I., Lorincz H., Harangi M., Fulop P., Paragh G. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int. J. Endocrinol., 2018; 2018: 9596054. doi: 10.1155/2018/9596054
13. Levine J.A., Oleaga C., Eren M., Amaral A.P., Shang M., Lux E., Vaughan D.E. Role of PAI-1 in hepatic steatosis and dyslipidemia. Scientific Reports, 2021; 11 (1): 1–13. doi: 10.1038/s41598-020-79948-x
14. Iida K., Tani S., Atsumi W., Yagi T., Kawauchi K., Matsumoto N., Hirayama A. Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study. Coronary Artery Disease, 2017; 28 (7): 577–587. doi: 10.1097/MCA.0000000000000521
15. Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mechanisms of Ageing and Development, 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004
16. Tripathi D., Kant S., Pandey S., Ehtesham N.Z. Resistin in metabolism, inflammation, and disease. The FEBS Journal, 2020; 287 (15): 3141–3149. doi: 10.1111/febs.15322
17. Singh A.K., Tiwari S., Gupta A., Natu S.M., Mittal B., Pant A.B. Аssociation of resistin with metabolic syndrome in Indian subjects. Metab. Syndr. Relat. Disord., 2012; 10 (4): 286–291. doi: 10.1089/met.2011.0128
18. Cabrera de Leon A., Almeida Gonzalez D., Gonzalez Hernandez A., Dominguez Coello S., Marrugat J., Juan Aleman Sanchez J., Brito Diaz B., Marcelino Rodriguez I., Perez Mdel C. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J. Atheroscler. Thromb., 2014; 21 (5): 454–462. doi: 10.5551/jat.22103
19. Melone M., Wilsie L., Palyha O., Strack A., Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/ kexin type 9. J. Am. Coll. Cardiol., 2012; 59 (19): 1697–1705. doi: 10.5551/jat.22103
20. Costandi J., Melone M., Zhao A., Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ. Res., 2011; 108 (6): 727–742. doi: 10.1161/CIRCRESAHA.110.238949
21. Park H.K., Kwak M.K., Kim H.J., Ahima R.S. Linking resistin, inflammation, and cardiometabolic diseases. The Korean Journal of Internal Medicine, 2017; 32 (2): 239. doi: 10.3904/kjim.2016.229
22. di Pietro N., Formoso G., Pandolfi A. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascular Pharmacology, 2016; 84: 1–7. doi: 10.1016/j.vph.2016.05.013
23. Fong L.G., Fong T.A., Cooper A.D. Inhibition of lipopolysaccharide-induced interleukin-1 beta mRNA expression in mouse macrophages by oxidized low density lipoprotein. J. Lipid. Res., 1991; 32: 1899– 1910. doi: 10.1016/S0022-2275(20)41893-0
24. Okumura T., Fujioka Y., Morimoto S., Masai M., Sakoda T., Tsujino T. Chylomicron remnants stimulate release of interleukin-1beta by THP-1 cells. J. Atheroscler. Thromb., 2006; 13: 438–450. doi: 10.5551/jat.13.38
25. Manica-Cattani M.F., Duarte M.M.M.F., Ribeiro E.E., de Oliveira R., da Cruz I.B.M. Effect of the interleukin-1B gene on serum oxidized low-density lipoprotein levels. Clin. Biochem., 2012; 45 (9): 641–645. doi: 10.1016/j.clinbiochem.2012.02.023
26. Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol. Rev., 2018; 98 (4): 2133–2223. doi: 10.1152/physrev.00063.2017
27. Föger B. Lipid lowering therapy in type 2 diabetes. Wien. Med. Wochenschr., 2011; 161 (11-12): 289–296. doi: 10.1007/s10354-011-0908-4
28. Monnier L., Hanefeld M., Schnell O., Colette C., Owens D. Insulin and atherosclerosis: how are they related? Diabetes & Metabolism, 2013; 39 (2): 111– 117. doi: 10.1016/j.diabet.2013.02.001
29. Aslan I., Kucuksayan E., Aslan M. Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients. Lipids in Health and Disease, 2013; 12 (1): 1–11. doi: 10.1186/1476-511X-12-54
30. Chaudhuri A., Dandona P. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, Obesity and Metabolism, 2011; 13 (10): 869–879. doi: 10.1111/j.14631326.2011.01423.x
31. Scherer T., Lindtner C., O’Hare J., Hackl M., Zielinski E., Freudenthaler A., Buettner C. Insulin regu- lates hepatic triglyceride secretion and lipid content via signaling in the brain. Diabetes, 2016; 65 (6): 1511–1520. doi: 10.2337/db15-1552
32. Nolan C.J., Ruderman N.B., Kahn S.E., Pedersen O., Prentki, M. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes, 2015; 64 (3): 673–686. doi: 10.2337/db14-0694
33. Izquierdo A.G., Crujeiras A.B., Casanueva F.F., Carreira M.C. Leptin, obesity, and leptin resistance: where are we 25 years later. Nutrients, 2019; 11 (11): 2704. doi: 10.3390/nu11112704
34. Lloyd D.J., McCormick J., Helmering J., Kim K.W., Wang M., Fordstrom P., Vйniant M. M. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48–/–Lepob/ob mice devoid of ApoE or Ldlr. Am. J. Physiol. Endocrinol. Metab., 2008; 294 (3): 496–505. doi: 10.1152/ajpendo.00509.2007
35. Bodary P.F., Gu S., Shen Y., Hasty A.H., Buckler J.M., Eitzman D.T. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler., Thrombosis, and Vascular Biol., 2005; 25 (8): 119–122. doi: 10.1161/01.ATV.0000173306.47722.ec
36. Metlakunta A., Huang W., Stefanovic-Racic M., Dedousis N., Sipula I., O’Doherty R.M. Kupffer cells facilitate the acute effects of leptin on hepatic lipid metabolism. Am. J. Physiol. Endocrinol. Metab., 2017; 312 (1): 11–18. doi: 10.1152/ajpendo.00250.2016
37. Huang W., Metlakunta A., Dedousis N., Ortmeyer H.K., Stefanovic-Racic M., O’Doherty R.M. Leptin augments the acute suppressive effects of insulin on hepatic very low-density lipoprotein production in rats. Endocrinology, 2009; 150 (5): 2169–2174. doi: 10.1210/en.2008-1271
38. Prieur X., Le May C., Magré J., Cariou B. Congenital lipodystrophies and dyslipidemias. Curr. Atheroscler. Rep., 2014; 16 (9); 1–11. doi: 10.1007/s11883-014-0437-x
39. Chong A.Y., Lupsa B.C., Cochran E.K., Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia, 2010; 53 (1): 27–35. doi: 10.1007/s00125-009-1502-9.
40. Salas-Salvadó J., Díaz-López A., Ruiz-Canela M., Basora J., Fitó M., Corella D., Martínez-González M.Á. Effect of a lifestyle intervention program with energyrestricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus trial. Diabetes Care, 2019; 42 (5): 777–788. doi: 10.2337/dc18-0836
41. Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Nat. Acad. Sci., 2003; 100 (12): 7265–7270. doi: 10.1073/pnas.1133870100
42. Sun R.L., Huang C.X., Bao J.L., Jiang J.Y., Zhang B., Zhou S.X., Zhang Y.L. CC-chemokine ligand 2 (CCL2) suppresses high density lipoprotein (HDL) internalization and cholesterol efflux via CCchemokine receptor 2 (CCR2) induction and p42/44 mitogen-activated protein kinase (MAPK) activation in human endothelial cells. J. Biol. Chem., 2016; 291 (37): 19532–19544. doi: 10.1074/jbc.M116.714279
43. Лазаренко В.А., Бобровская Е.А., Путинцева Е.В., Бондарев Г.А. Окисленные липопротеины низкой плотности до и после реконструктивных вмешательств на магистральных артериях нижних конечностей. Вестник Национального медико-хирургического центра им. Н.И. Пирогова, 2015; 10 (1): 14–17. www.elibrary.ru/item.asp?id=26713873
44. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev., 2012; 64 (2): 238–258. doi: 10.1124/pr.111.005108
45. Minnone G., de Benedetti F., Bracci-Laudiero L. NGF and its receptors in the regulation of inflammatory response. Int. J. Mol. Sci., 2017; 18 (5): 1028. doi: 10.3390/ijms18051028
46. Mantyh P.W., Koltzenburg M., Mendell L.M., Tive L., Shelton D.L., Warner D.S. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. The J. Am. Soc. Anesthesiol., 2011; 115 (1): 189–204. doi: 10.1097/ALN.0b013e31821b1ac5
47. Do H.T., Bruelle C., Pham D.D., Jauhiainen M., Eriksson O., Korhonen L.T., Lindholm D. Nerve growth factor (NGF) and pro-NGF increase lowdensity lipoprotein (LDL) receptors in neuronal cells partly by different mechanisms: role of LDL in neurite outgrowth. J. Neurochem., 2016; 136 (2): 306–315. doi: 10.1111/jnc.13397
48. Teplan V., Senolt L., Hulejova H., Stollova M., Gurlich R. Early changes in serum visfatin after abdominal surgery: a new pro-inflammatory marker in diagnosis? Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2014; 159 (3): 489–496. doi: 10.5507/bp.2014.012
49. Кузнецова Л.А., Шпаков А.О. Адипокины и их возможная роль в ожирении и сахарном диабете 2-го типа. Саратовский научномедицинский журнал, 2018; 14 (2): 201–206. www.elibrary.ru/item.asp?id=3574179
50. Naz R., Tauqeer S., Bibi Y., Ayub M. Level of visfatin in obese and diabetic Balb/c mice. Pak. J. Physiol., 2017; 13 (3): 36–38. www.pps.org.pk/PJP/13-3/Raeesa.pd
51. Shafeeq N.K. Visfatin PON-1 Levels in Iraqi Hyperthyroidism Patient’s with Dyslipidemia. Indian J. Clin. Biochem., 2019; 34 (1): 101–107. doi: 10.1007/s12291-017-0717-7
52. Бардымова Т.П., Березина М.В., Батунова Е.В., Мирошниченко И.А. Метаболические особенности пациентов с ожирением. Медицинский совет, 2017; 20: 157–159. doi: 10.21518/2079-701X-2017-20-157-159
53. Pan X., Kaminga A.C., Wen S.W., Acheampong K., Liu A. Omentin-1 in diabetes mellitus: A systematic review and meta-analysis. PLoS One, 2019; 14 (12): e0226292. doi: 10.1093/cvr/cvw016.
54. Lesná J., Tichá A., Hyšpler R., Musil F., Bláha V., Sobotka L., Šmahelová A. Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutrition & Diabetes, 2015; 5 (11): 183–183. doi: 10.1038/nutd.2015.33
55. Moreno-Navarrete J.M., Catalán V., Ortega F., Gómez-Ambrosi J., Ricart W., Frühbeck G., Fernández-Real J.M. Circulating omentin concentration increases after weight loss. Nutrition & Metabolism, 2010; 7 (1): 1–6. doi: 10.1186/1743-7075-7-27
56. Watanabe K., Watanabe R., Konii H., Shirai R., Sato K., Matsuyama T.A., Ishibashi-Ueda H., Koba S., Kobayashi Y., Hirano T., Watanabe T. Counteractive effects of omentin-1 against atherogenesis. Cardiovasc. Res., 2016; 110 (1): 118–128. doi: 10.1093/cvr/cvw016